Martin Landray is Professor of Medicine & Epidemiology at the Nuffield Department of Population Health, University of Oxford, and Chief Executive of Protas, a not-for-profit organization that facilitates the design and delivery of large randomised trials of interventions for common diseases. He is co-chief investigator of the RECOVERY trial, which has enrolled 48,000 hospitalised patients with COVID-19. The trial identified that dexamethasone and tocilizumab reduce mortality but that many widely used treatments, including hydroxychloroquine have no meaningful impact on patient survival. He is an advisor to the European Society of Cardiology Regulatory Affairs Committee & leads the Good Clinical Trials Collaborative which works to improve the quality of clinical trial regulations and guidelines.